Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
The NAD(+) depending enzyme SIRT1 regulates the mitochondrial biogenesis, fat and glucose metabolism through catalyzing the deacetylation of several metabolism-related protein-substrates. Recently, synthetic activators of SIRT1 referred to as STACs (Sirtuin activating compounds, e.g. SRT2104) were identified and tested in clinical studies for the treatment of aging-related diseases such as type 2 diabetes, Alzheimer's and obesity. Although the mechanism of SIRT1 activation by small molecules has caused considerable controversy, STACs demonstrated a significant performance enhancement in mice experiments including an improvement of endurance, muscle strength, and locomotor behavior. Due to their potential to increase exercise tolerance in healthy individuals, SIRT1 activators are currently being monitored by anti-doping authorities. In the present study, the in vivo metabolic clearance of three SIRT1 activators was investigated in rats by the collection of urine, DBS (dried blood spots) and plasma samples following a single oral administration. The resulting metabolic products were studied by positive electrospray ionization - (tandem) mass spectrometry and confirmed by the comparison with in vitro generated metabolites using human and rat liver microsomal preparations. Subsequently, a screening procedure for five SIRT1 activators and the metabolite M1-SRT1720 in DBS specimens was developed. Liquid-liquid-extraction and liquid chromatography/tandem mass spectrometry was employed based on diagnostic ion transitions recorded in multiple reaction monitoring mode and two deuterated internal standards namely d8-SRT1720 and d8-M1-SRT1720 were utilized. The doping control assay was characterized with regard to specificity, limit of detection (10-50ng/ml), recovery (65-83%) and imprecision (7-20%) and ion suppression/enhancement effects (<10%), demonstrating its fitness-for-purpose for sports drug testing applications.
Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Germany.
Sebastian
S
Höppner
Philippe
P
Delahaut
Wilhelm
W
Schänzer
Mario
M
Thevis
D000284:Administration, Oral; D000818:Animals; D002853:Chromatography, Liquid; D004300:Doping in Sports / Q000517:prevention & control; D059788:Dried Blood Spot Testing; D005260:Female; D006576:Heterocyclic Compounds, 4 or More Rings / Q000097:blood / Q000652:urine; D006801:Humans; D007477:Ions; D059625:Liquid-Liquid Extraction; D008099:Liver / Q000378:metabolism; D008862:Microsomes, Liver / Q000378:metabolism; D004364:Pharmaceutical Preparations / Q000097:blood* / Q000652:urine; D051381:Rats; D017208:Rats, Wistar; D012015:Reference Standards; D015203:Reproducibility of Results; D056564:Sirtuin 1 / Q000378:metabolism*; D021241:Spectrometry, Mass, Electrospray Ionization; D015813:Substance Abuse Detection / Q000379:methods*; D053719:Tandem Mass Spectrometry
D006576:Heterocyclic Compounds, 4 or More Rings; D007477:Ions; D004364:Pharmaceutical Preparations; C525422:SRT1720; C447939:SIRT1 protein, human; D056564:Sirtuin 1
DBS; Doping; Metabolism; SRT1720; SRT2104